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Summary 
Uterine leiomyosarcoma (ULMS) develops more often in the muscle tissue layer of the 
uterine body than in the uterine cervix. The development of gynecologic tumors is often 
correlated with female hormone secretion; however, the development of uterine ULMS is not 
substantially correlated with hormonal conditions, and the risk factors are not yet known. 
Importantly, a diagnostic-biomarker which distinguishes malignant ULMS from benign tumor 
leiomyoma (LMA) is yet to be established. Accordingly, it is necessary to analyze risk factors 
associated with uterine ULMS, to establish a treatment method. Proteasome low-molecular 
mass polypeptide 2(LMP2)/β1i-deficient mice spontaneously develop uterine LMS, with a 
disease prevalence of ~40% by 14 months of age. We found LMP2/β1i expression to be 
absent in human LMS, but present in human LMA. Therefore, defective-LMP2/β1i 
expression may be one of the risk factors for ULMS. LMP2/β1i is a potential 
diagnostic-biomarker for uterine ULMS, and may be a targeted-molecule for a new 
therapeutic approach. (153 words) 
 
The uterus, the organ in which the embryo grows, is composed of three layers, the uterine 
endometrium which serves as a bed for the embryo; the myometrium of the wall which 
protects the embryo; and a serous membrane enveloping the uterus. In general, the term 
uterine tumor refers to an epithelial malignant tumor of the uterus, which is roughly classified 
as a tumor of the uterine cervix or the uterine body. Because of the prevalence of screening, 
uterine cervix cancer is decreasing in incidence, and usually detected at a very early stage. In 
contrast, cancer of the uterine body is increasing in incidence, and rarely detected at the initial 
stages. While most tumors of the uterine body are adenocarcinomas (derived from the 
subintimal gland), tumors of the uterine cervix are classified into squamous cancer and 
adenocarcinoma. Smooth muscle tumors (SMTs) which develop in the myometrium have 
been traditionally divided into benign LMA and malignant ULMS based on cytological atypia, 
mitotic activity and other criteria. Uterine LMS is relatively rare, having an estimated annual 
incidence of 0.64 per 100,000 women
1
. ULMS accounts for 2% to 5% of tumors of the 
uterine body and develops more often in the muscle layer of the uterine body than in the 
uterine cervix.
 
As uterine ULMS is resistant to chemotherapy and radiotherapy, surgical 
intervention is virtually the only means of treatment
2-4
. The prognosis for uterine ULMS is not 
good, and the five-year survival rate is approximately 35%
5
. However, developing an efficient 
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adjuvant therapy is expected to improve this. Uterine LMA may occur in as many as 
70%~80% of women by the age of 50 years
6
. Distinguishing uterine LMA from uterine 
ULMS is very difficult, and a diagnosis generally requires surgery and cytoscopy
7
. Diagnostic 
categories for uterine SMTs and morphological criteria are used to assign cases
8,9
 (NOTE 1). 
The non-standard subtypes of uterine SMTs such as the epithelioid and myxoid types are 
classified in a different way using these features, so the establishment of a diagnostic method 
for the identification of non-standard smooth muscle differentiation is important
8,9
. 
   High estrogen levels are considered to significantly influence the development of tumors 
in the uterine body
10-12
. The molecular mechanisms by which uterine LMA and ULMS 
develop are not yet known, though tumors that have developed in the myometrium for some 
reason gradually become larger due to the influence of the female hormone, estrogen, and 
generate tumors. However, no correlation between the development of uterine ULMS and 
hormonal conditions, and no obvious risk factors have been found. Although cases 
accompanied by hypocalcaemia or eosinophilia have been reported, neither clinical 
abnormality is an initial risk factor for uterine ULMS. The identification of a risk factor 
associated with the development of uterine ULMS would significantly contribute to the 
development of preventive and therapeutic treatments. 
Cytoplasmic proteins are mostly degraded by a protease complex, which has many 
substrates consisting of twenty-eight 20 to 30-kDa subunits, referred to as the 20S proteasome, 
and it is located in the nucleus and the cytoplasm
13,14
. The proteasomal degradation is 
essential for many cellular processes, including the cell cycle, the regulation of gene 
expression and immunological function
15
. Interferon-γ (IFN-γ) induces the expression of large 
numbers of responsive genes, proteasome subunits, i.e., LMP2/β1i, LMP7/β5i, and 
LMP10/β2i
16
. The individual expression of the low molecular weight protein (LMP)2, LMP7, 
and LMP10(MECL-1) subunits is believed to contribute to the initiation and development of 
disorders. A recent study revealed a unique role for LMP7 in controlling pathogenic immune 
responses and provided a therapeutic rationale for targeting LMP7 in autoimmune disorders, 
especially rheumatoid arthritis
17
. Recent reports demonstrate LMP2/β1i, as obligatory for 
tumor surveillance and demonstrate a tissue-specific role for LMP2/β1i in protection from 
spontaneous uterus neoplasms
18,19
.  
Homozygous mice deficient in LMP2/β1i show tissue- and substrate-dependent 
abnormalities in the biological functions of the proteasome
18,20
. ULMS reportedly occurred in 
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female LMP2/β1i-null
 
mice at age 6 months or older, and the incidence at 14 months of age 
was about 40%
19,20
. The curve indicating the incidence in mice is similar to that indicating the 
incidence of human ULMS, which occurs after menopause. Histological studies of 
LMP2/β1i-null uterine tumors have revealed characteristic abnormalities of ULMS
19
. The 
tumors lacked lymphoid infiltrates, a sign of immune recognition, and consisted of uniform 
elongated myometrium cells arranged into bundles. The nuclei of the tumor cells varied in 
size and shape, furthermore, mitosis was frequent. In contrast, the myometrium cells of 
C57BL/6 mice were normal in appearance
19
. Whereas relatively few Ki-67-positive cells, the 
proliferating cells of solid tumors, were observed in the basal cell layer of the normal 
myometrium, most of the basal cells vividly expressed Ki-67 in LMP2/β1i-null mice
19
. This 
immunological staining indicates abnormal proliferation of the LMP2/β1i-lacking cells in the 
basal layer. LMP2/β1i-null mice that have developed uterine ULMS undergo considerable 
weight loss, and then die by 14 months of age. The LMP2/β1i-null mice also exhibit skeletal 
muscle metastasis from ULMS
21
. Therefore it is likely that LMP2/β1i-null mice with uterine 
LMS die as a result of the tumor mass and metastasis. In general, it is not easy to distinguish 
uterine LMA from ULMS, however, in mice, because of such characteristic pathological 
findings, significant weight loss, and skeletal muscle metastasis, a tumor that develops in the 
uterus of an LMP2/β1i-null mouse can be considered malignant, i.e., a ULMS
19,20
. 
Furthermore, IHC revealed a serious loss in the ability to induce LMP2/β1i expression in 
human ULMS tissue in comparison with LMA or normal myometrium located in the same 
section
22,23
. Of the 54 cases we examined with ULMS, 46 were negative for LMP2/β1i 
expression, 4 were focally positive, and 2 were partially positive
23
. Two ULMS cases were 
stained for LMP2/β1i. LMP2/β1i levels were also evaluated in skeletal muscle and rectum 
metastases from individual ULMS patients
23
. Pathological examination of surgical samples 
showed the presence of a mass measuring 3 cm in its largest diameter in the lumbar quadrate 
muscle without a fibrous capsule. All lymph nodes were negative for ULMS metastases, and 
IHC analyses showed positivity for Ki-67 and negativity for LMP2/β1i
23
. Histological 
findings were consistent with metastatic LMS for the skeletal muscle and rectum lesions
23
. In 
western blotting and RT-PCR experiments, LMP2/β1i was expressed in normal myometrium, 
but not in human ULMS, both strongly supportive of the IHC findings
22,23
. Although we has 
previously demonstrated that the abnormal expression of the ovarian steroid receptors, TP53 
and Ki-67 and mutations of TP53 were frequently associated with ULMS, defective LMP2 
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expression appears to be more characteristic of ULMS than these factors
22-24
. 
In the case of gynecological cancers, such as breast cancer, a female hormonal imbalance is 
often a risk factor for developing tumors
10-12
. As in the case of uterine LMA, however, a 
correlation between the development of ULMS, the female hormone, and hormone receptors 
has yet to be elucidated. A recent report showed the expression of Lmp2/β1i mRNA and 
protein in luminal and glandular epitheliua, placenta villi, trophoblastic shells, and arterial 
endothelial cells
25-27
. These results implicate LMP2/β1i in the invasion of placental villi, 
degradation of the extracellular matrix, immune tolerance, glandular secretion, and 
angiogenesi
-27
. The present study should help to elucidate the regulatory role of LMP2/β1i in 
the implantation of embryos
25-27
. Further experiments are al so required to elucidate the 
molecular mechanism of ULMS tumorigenesis involved biological significance of LMP2. 
The LMP2/β1i -null mouse was the first animal model of spontaneous ULMS to be 
established. Defective LMP2/β1i expression may be one of the causes of ULMS. To 
demonstrate whether LMP2/β1i is a potential biomarker for distinguishing ULMS from LMA, 
we are investigating the reliability and characteristics of LMP2/β1i as a diagnostic indicator 
with several clinical research facilities. The clinical research is yet to be concluded, and 
large-scale clinical studies need to be performed. Histologic and immunohistochemistry 
characteristics of uterine mesenchymal tumors including STUMP are summarized in Table 1. 
Clarification of the correlation between these factors and the development of ULMS and the 
identification of specific risk factors may lead to the development of new treatments for the 
disease. ULMS is refractory to chemotherapy and has a poor prognosis. The molecular 
biological and cytological information obtained from LMP2-null mice will contribute 
remarkably to the development of preventive methods, a potential diagnostic-biomarker, and 
new therapeutic approaches against ULMS. 
 
(NOTE 1) The typical gross appearance is a large (>10cm), poorly circumscribed mass with a 
soft, fleshy consistency and a variegated cut surface that is grey-yellow to pink, with foci of 
hemorrhage and necrosis
8,9
. The histologic classification of uterine sarcomas is based upon 
homology to normal cell types and include ULMS (analogous to myometrium), stromal 
sarcoma (analogous to endometrial stroma), and other heterologous cell types (i.e., 
osteosarcoma, liposarcoma). Microscopically, most ULMS are overtly malignant, with 
hypercellularity, coagulative tumor cell necrosis, abundant mitoses (>10 to 20 mitotic figures 
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(mf) per 10 high power fields (hpf)), atypical mitoses, cytologic atypia, and infiltrative 
borders. Mitotic rate is the most important determinant of malignancy, but is modified by the 
presence of necrosis and cytologic atypia. The diagnosis of ULMS may be made in the 
presence of tumor necrosis and any mitoses. In the absence of tumor necrosis, the diagnosis 
can be made with moderate to severe cytologic atypia and a mitotic index greater than 
10mf/10hpf. Without tumor necrosis and significant atypia, a high mitotic index is compatible 
with a benign clinical course, however, data is limited
8,9
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Table 1  
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